The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C.
about
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV TherapyMedication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions.Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.Safety of direct-acting antivirals in the treatment of chronic hepatitis C.Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.Antiviral drug discovery: broad-spectrum drugs from nature.Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice.The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions.Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection.Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort.Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence.Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens.Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection.[New direct-acting antiviral agents for the treatment of chronic hepatitis C in 2014].Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016.
P2860
Q28080752-6448D3E1-127C-4505-9745-2749034CB629Q34143327-EFCDEC42-491C-4FBD-8417-41D54DE69FEEQ34255562-AA1ED552-137A-4DD5-B7AA-C3A29D511B1BQ37685473-2104E3DE-92F1-4211-B186-A790B5468ECAQ38175491-AA2232FA-0174-4D35-9CD5-1F39BCE1AC64Q38189110-DF023755-45B0-4A20-8642-314A34B2CC48Q38203823-04BCF611-6191-4C7F-B6A0-53EEC1969520Q38260235-EF740EAD-F87A-4727-B91C-04CB600BA61EQ38606309-FFE06544-DCFC-4D13-A896-3AE0E3D9E86AQ38621245-7C360D16-BB8C-47F2-911F-F1533A5E27ADQ38929010-D5ABF7E9-3E26-450C-A6D4-BD10B87BD57FQ40567336-783A21AD-CCCF-4EFE-A0D7-8B857FFFFC65Q41092963-C46F8C7A-9BAC-4D87-9246-8E18E6217903Q41668808-D4B010CE-8F77-42CA-BED2-CD09F742D9D7Q49200882-BB0CFF4A-18FC-4C5E-BF53-7C952F22DD15Q50283110-3071210F-7B40-4E17-B181-0E5ECB63818CQ50283732-A982A298-76D0-4A04-88B0-FCDEF7001BF7Q55093102-B1F2C60F-610E-46B6-9983-A5072F3278DC
P2860
The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The clinical significance of d ...... s against chronic hepatitis C.
@en
type
label
The clinical significance of d ...... s against chronic hepatitis C.
@en
prefLabel
The clinical significance of d ...... s against chronic hepatitis C.
@en
P2093
P2860
P356
P1476
The clinical significance of d ...... ts against chronic hepatitis C
@en
P2093
A A Markova
B Calle Serrano
H Wedemeyer
P2860
P304
P356
10.1111/APT.12523
P407
P577
2013-10-16T00:00:00Z